SCHEMBL2233536

SCHEMBL2233536

CCN1CCN(Cc2ccc(Nc3ncnc4c(C(=O)Nc5c(Cl)c(OC)c(Br)c(OC)c5Cl)csc34)cc2C(F)(F)F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 10/20 0.45
MAP4K2 Q12851 10/20 0.45
FES P07332 4/20 0.45
FER P16591 4/20 0.45
MAPK14 Q16539 8/20 0.44
MAP3K20 Q9NYL2 5/20 0.44
CSK P41240 4/20 0.44
EPHA2 P29317 3/20 0.44
HCK P08631 7/20 0.44
NR2C2 P49116 6/20 0.44
GCK P35557 3/20 0.44
MAP4K4 O95819 2/20 0.43
ABL1 P00519 2/20 0.43
RAF1 P04049 2/20 0.43
LYN P07948 2/20 0.43
SRC P12931 2/20 0.43
EPHB2 P29323 2/20 0.43
ABL2 P42684 2/20 0.43
EPHB4 P54760 1/20 0.43
MKNK2 Q9HBH9 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125158 0.96 MAP3K7 (0.44) MAP3K7MAP4K2FESFERMAPK14
SCHEMBL2235409 0.91 MAP3K7 (0.49) MAP3K7MAP4K2FESFERMAPK14
SCHEMBL14125163 0.90 MAP3K7 (0.51) MAP3K7MAP4K2FESFERMAPK14
SCHEMBL14137340 0.88 PIK3C3 (0.44) ABL1RAF1LYNSRCRET
SCHEMBL2231261 0.85 PIK3C3 (0.54) ABL1RAF1LYNSRCRET
SCHEMBL14125153 0.84 PIK3C3 (0.42) ABL1RAF1LYNSRCRET
SCHEMBL2232895 0.84 PIK3C3 (0.43) MAP3K7ABL1RAF1LYNSRC
SCHEMBL2232833 0.84 FGFR3 (0.47) MAP3K7ABL1RAF1LYNSRC
SCHEMBL2232592 0.84 PIK3C3 (0.42) MAP3K7ABL1RAF1LYNSRC
SCHEMBL2233308 0.82 AURKA (0.42) ABL1RAF1LYNSRCRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 MAP3K7 17/4885MAP4K2 55/4885FES 1029/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 MAP3K7 17/4885MAP4K2 55/4885FES 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.